4Moving Biotech announces successful results from its Lasare Phase I 4P004 Clinical Trial intraarticular Liraglutide for knee osteoarthritis patients
4Moving Biotech, a spin-off of 4P-Pharma committed to developing first-in-class treatments to modify the natural course of knee osteoarthritis, announces the successful achievement of the Phase 1 Lasare trial in knee osteoarthritis (OA) patients using 4P004.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240609275171/en/
(Graphic: Business Wire)
Lasare Phase I trial is a multi-center, randomized, double-blinded, placebo-controlled involving 34 patients across three sites in Belgium.
The study evaluated the safety, tolerability, and pharmacokinetics of ascending doses of a single intra-articular injection of liraglutide (4P004).
The trial reached its primary objective, confirming that intraarticular liraglutide (4P004) was safe and well tolerated. A pharmacological active dose has been identified, with similar expected adverse events (EAEs) in the 4P004 groups as the placebo group. Pharmacokinetics, both observed and simulated Cmax values, also indicated lower systemic exposure than reported for subcutaneous liraglutide injection from the approved product, Victoza®, affirming the company’s plan to pursue a 505(b)(2) regulatory pathway in the US for 4P004.
Pr. Francis Berenbaum, Co-founder and Chief Medical Officer of 4Moving Biotech, declared: "The Success of the Phase 1 study of 4P004 underscores the quality of our advancements in the quest for therapeutic solutions for patients suffering from knee osteoarthritis. Furthermore, with the established safety and tolerability profiles, we are progressing confidently to the next stage of clinical development with 4P004."
As for ultimate goal, 4Moving Biotech’s strategy intends to secure accelerated approvals in the US and EU for early market entry at the end of the planned Phase 2b efficacy and safety trial. Toward this goal, the company recently received constructive pre-IND guidance from the FDA, translating 4Moving Biotech’s planned potential accelerated approval driven strategy into a highly differentiated clinical program catalyzed by a unique combination of reasonably likely surrogate endpoints, supported by sophisticated in silico AI-based prognostic modelling.
Revital Rattenbach, Chairwoman of 4Moving Biotech, stated: "Beyond the positive results from our phase I clinical study on knee osteoarthritis, the FDA's positive echoing has built a tremendous momentum for our accelerated strategy to the market, with hopes to bring to OA patients the first therapy being able to modify the natural course of the disease."
About 4Moving Biotech
Incorporated in mid 2020 as a spin-off of 4P-Pharma, 4Moving Biotech is a clinical stage biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD). Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis. The company is headquartered at the Pasteur Institute in Lille, France.
Website: https://www.4movingbiotech.com/
LinkedIn: https://fr.linkedin.com/company/4moving-biotech
About Lasare
This project has received funding from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and innovation program. The funding agencies supporting this work are (in alphabetical order of participating countries): France: BPI France ; Germany: Project Management Agency (DLR), which acts on behalf of the Federal Ministry of Education and Research (BMBF); The Netherlands: Netherlands Enterprise Agency (RVO); Switzerland: Innosuisse (the Swiss Innovation Agency).
The only version of the 4Moving Biotech press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240609275171/en/
Contact information
Press :
Emmanuel Dadje
Communication Manager
+33 6 30 06 12 13
emmanuel.dadje@4P-Pharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aqara Expands Security Camera Portfolio with First Doorbell Camera Hub10.7.2025 10:00:00 EEST | Press release
Aqara, a global leader and pioneer in IoT, today announced the global availability of its next-generation video doorbell, the Doorbell Camera Hub G410. This 2K doorbell camera features enhanced image quality, a built-in presence sensor, on-device facial recognition, and seamless smart home integration. It also functions as a multi-protocol Matter hub, offering users a versatile solution for connecting their indoor and outdoor smart devices. Equipped with dual-band Wi-Fi (2.4GHz/5GHz), Thread, Zigbee, and Bluetooth connectivity, the Doorbell Camera Hub G410 is designed to be the cornerstone of a smart home. As a Matter Controller, Thread Border Router, and Aqara Zigbee hub, it not only connects an assortment of Aqara devices but also supports more than 50 types of third-party Matter-compatible devices. These include locks, sensors, switches, lights, and even newer connected products like robovacs, home appliances, and EV chargers. The G410 captures every detail at the doorstep with its
Future Scientists From Europe Shine in Global Cambridge Schools Science Competition10.7.2025 09:45:00 EEST | Press release
Three student teams from schools across Europe have won awards in the 2025 Cambridge Science Competition, run by the International Education group at Cambridge University Press & Assessment (Cambridge). The winning teams are from Türkiye, Ukraine, and Czech Republic and were selected by an expert panel of judges at the University of Cambridge for the high calibre of their projects, each of which aim to tackle real-world sustainability issues. The global Cambridge Science Competition, an extracurricular program for students aged 14–16, fosters a passion for innovation, research and critical thinking while honing practical lab skills. Participants are challenged to design projects with real-world relevance to their schools or communities, focusing on sustainability. This year, the competition saw record entries from student teams who are studying for Cambridge IGCSE science qualifications, taught across 6,000 schools globally. Best in Europe winner – Türkiye Students from Beştepe College
IFF Expands Innovation Center in Singapore with New Immersive Experience Hub10.7.2025 07:00:00 EEST | Press release
IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today unveiled its new Immersive Experience Hub located within its Singapore Innovation Center. The multi-sensory facility enables IFF to work alongside customers to conceptualize, test, and refine product ideas in simulated real-world environments—enhancing decision-making, shortening development timelines and improving go-to-market success. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709079831/en/ “The new space builds on IFF’s $30 million investment in Singapore in 2022, strengthening our position as a strategic innovation hub for Asia,” said Ramon Brentan, site leader of the IFF Singapore Innovation Center and vice president, regional general manager for Greater Asia, Scent. “The immersive space transforms how we engage with customers and supports our broader innovation strategy in a region expected to drive 60 percent
Murata Begins World’s First Mass Production of 47μF Multilayer Ceramic Capacitor in 0402-inch Size10.7.2025 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has begun the world’s first mass production of the 0402-inch size (1.0 × 0.5 mm) multilayer ceramic capacitors (MLCC) with a capacitance of 47μF*. The new product line, available in two variants with different temperature characteristics, is designed to advance MLCC miniaturization and enhance customer system performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709615978/en/ [Murata Manufacturing Co., Ltd.] 47µF MLCC in 0402-inch Size In recent years, high-performance IT solutions, such as those used in AI servers and data centers, have seen rapid growth. Due to the often high component density demanded by these devices, optimized component placement within limited PCB areas is paramount. As a result, there is increasing demand for capacitors that offer both miniaturization and higher capacitance, along with high reliability under high-temperature co
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development10.7.2025 03:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a global licensing agreement with BeOne Medicines Ltd., a global oncology company, for multiple fully human antibodies. Prior to this licensing agreement, BeOne Medicines had obtained a license to use Biocytogen’s RenMice® fully human antibody platform. Building on this established collaboration, the new agreement expands the partnership into antibody license, further strengthening the strategic relationship between the two companies. Dr. Yuelei Shen, President and CEO of Biocytogen, said, “BeOne Medicines is a global leader in drug development, and we are thrilled to enter into this strategic collaboration. The antibodies licensed under this agreement were discovered using our proprietary RenMice® fully human antibody platform, highlighting o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom